0.5% Hydrochloride Bupivacaine 20ml: 0.5% Hydrochloride Bupivacaine 20ml for ISBPB
0.5% Hydrochloride Bupivacaine 10ml: 0.5% Hydrochloride Bupivacaine 10ml for ISBPB
Liposomal Bupivacaine 10mL: Liposomal Bupivacaine 10mL for ISBPB
Study summary
The study aims to evaluation the effects of Liposomal Bupivacaine on diaphragmatic function in patients undergoing upper limb surgery who receive Interscalene Brachial Plexus Block. A total of 120 eligible patients will be enrolled and divided into two groups: Group A will receive 20ml of 0.5% Hydrochloride Bupivacaine , while Group B will receive 10ml of 0.5% Hydrochloride Bupivacaine plus 10ml of Liposomal Bupivacaine. Assessments of diaphragmatic function, pulmonary function, and pain intensity will be performed before the block and at different time points after the block, with follow-up for adverse events. The study is scheduled to run from September 2025 to September 2026, with strict adherence to privacy protection and ethical guidelines.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Patients undergoing upper limb surgery scheduled for interscalene brachial plexus block
* Aged ≥ 18 years
* American Society of Anesthesiologists (ASA) physical status I-III
Exclusion Criteria:
* Known allergy or intolerance to amide local anesthetics
* Nerve injury in the upper limb on the surgical side
* Coagulopathy
* Used opioid medications continuously for more than 3 weeks before surgery
* History of pulmonary disease and a pulse oxygen saturation (SpO₂) \< 95% (measured after 5 minutes of rest at room temperature without oxygen supplementation, using a transcutaneous pulse oximeter)
* Refuse to participate or are deemed unsuitable for this trial by the researchers
Withdrawal Criteria:
* Patients voluntarily withdrew their informed consent
* Surgery was canceled or the anesthesia method was changed due to surgical factors before interscalene brachial plexus block
Primary outcome measure(s)
Identification the recovery time of diaphragmatic function after diaphragmatic paralysis caused by interscalene brachial plexus block — From the initiation of interscalene brachial plexus block to the recovery of diaphragmatic function (within approximately 72 hours)
Trial sites (1)
Facility
City
Region
Status
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, zhejiang 310000
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.